

Synovial sarcoma of the head and neck: a single institution review

Vancheswaran Gopalakrishnan,¹ Behrang Amini,² Michael J Wagner,³ Erica N. Nowell,⁴ Alexander Lazar,⁵ Patrick P. Lin,⁶ Robert S. Benjamin,⁴ and Dejka M. Araujo⁴

Supplemental materials

Supplemental table S1: Median progression-free and overall survival based on timing of radiation or chemotherapy

	Median PFS (in yrs)	Log-rank p	Median OS (in yrs)	Log-rank p
Radiation (n=36)		0.331		0.072
Adjuvant (n=30)	5.41		7.9	
Neoadjuvant (n=5)	NA		NA	
Peri-operative (n=1)	2.23		4.26	
Chemotherapy (n=26)		0.87		0.118
Neoadjuvant (n=13)	3.95		4.52	
Adjuvant (n=13)	4.58		NA	

Supplemental table S2: Overall survival by choice of therapeutic regimen after recurrence

	N (%)	Median OS [#] (in years)	Log-rank p
Local therapy only	5 (0.25) ^a	3.4	0.643
Local therapy + Additional systemic therapy	9 (0.45) ^b	2.47	
Systemic therapy only	5 (0.25)	2.33	

^a: 3 patients underwent surgery, 2 underwent surgery plus local radiation therapy

^b: 8 patients got surgery + adjuvant chemotherapy. 1 patient got surgery + radiation + adjuvant chemotherapy

OS was calculated as the interval between date of diagnosis of recurrent disease to date of death or last contact